Post job

Elanco main competitors are Warner Chilcott, Merck, and U.S. Pharmacopeia.

Competitor Summary. See how Elanco compares to its main competitors:

  • Roche Holding AG has the most employees (94,442).
  • Employees at Warner Chilcott earn more than most of the competitors, with an average yearly salary of $92,301.
  • The oldest company is U.S. Pharmacopeia, founded in 1820.
Work at Elanco?
Share your experience

Elanco vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
1954
4.9
Greenfield, IN2$4.4B10,200
1952
4.9
Parsippany-Troy Hills, NJ6$9.3B11,300
1891
4.6
Kenilworth, NJ31$64.2B74,000
1968
4.2
Rockaway, NJ1$105.1M3,000
1984
4.6
Cranbury, NJ3$4.2B32,000
1987
4.7
South San Francisco, CA1$61.0B94,442
1984
4.9
Parsippany-Troy Hills, NJ1$5.9B21,600
1946
4.9
Eatontown, NJ7$150.0M249
1867
4.8
Hazelwood, MO5$1.0B3,400
1961
4.8
Canonsburg, PA2$11.5B35,000
1977
4.3
Minneapolis, MN1$100.5M51
1820
4.8
Rockville, MD4$170.0M750
1954
4.8
Billerica, MA1$7.2B6,100
2004
4.3
Greenwich, CT1$100.0M1,733
1931
3.8
Waltham, MA1$81.0M30,000
1956
4.7
Billerica, MA3$1.5B612
2007
4.5
Los Angeles, CA1$359.0M885
1974
4.0
West Lafayette, IN3$23.5M421
1849
4.1
Melville, NY1-750
1981
4.8
Duluth, GA1$2.7B6,900
1951
4.9
Saint Louis, MO2$2.8B9,600

Elanco competitors jobs

Elanco jobs openings vs similar companies

If you’re looking for a job, here are the jobs openings at Elanco and its competitors.

Elanco remote jobs

Rate Elanco's competitiveness in the market.

Zippia waving zebra

Elanco salaries vs competitors

Among Elanco competitors, employees at Warner Chilcott earn the most with an average yearly salary of $92,301.

Compare Elanco salaries vs competitors

CompanyAverage salaryHourly salarySalary score
Elanco
$70,606$33.95-
Zoetis
$87,092$41.87-
Merck
$90,328$43.43-
Warner Chilcott
$92,301$44.38-
Sun Pharmaceutical Industries Inc.
$72,061$34.64-
Roche Holding AG
$57,325$27.56-

Compare Elanco job title salaries vs competitors

CompanyHighest salaryHourly salary
Elanco
$143,514$69.00
Abraxis BioScience
$159,805$76.83
Warner Chilcott
$154,096$74.08
Merial Limited
$150,927$72.56
Merck
$149,954$72.09
Zoetis
$149,897$72.07
Watson Pharma Pvt Ltd
$147,589$70.96
U.S. Pharmacopeia
$143,487$68.98
Mylan
$143,139$68.82
Roche Holding AG
$141,857$68.20
BASi
$141,710$68.13
West-Ward Pharmaceuticals
$141,385$67.97
Sigma-Aldrich
$140,973$67.78
Asahi Kasei America
$140,635$67.61
Aptuit
$140,257$67.43
Sun Pharmaceutical Industries Inc.
$139,543$67.09
Fougera Pharmaceuticals
$137,634$66.17
Paddock Laboratories
$137,203$65.96
Lantheus
$136,891$65.81
EMD Millipore
$136,585$65.67

Do you work at Elanco?

Does Elanco effectively differentiate itself from competitors?

Elanco jobs

Elanco demographics vs competitors

Compare gender at Elanco vs competitors

Job titleMaleFemale
BASi47%53%
Elanco52%48%
Merck54%46%
Roche Holding AG56%44%
EMD Millipore57%43%
Mylan57%43%
Male
Female

Compare race at Elanco vs competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity score
68%10%11%7%4%
9.7
67%10%11%9%3%
7.4
56%16%10%14%4%
9.8
62%14%6%15%3%
9.8
62%18%7%10%3%
9.3
57%17%10%12%4%
9.8

Elanco and similar companies CEOs

CEOBio
Brian R. Bond
BASi

Mary Anne Heino
Lantheus

Mary Anne Hein is a President & CEO at LANTHEUS HOLDINGS, INC..

Robert M. Davis
Merck

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Juan Ramón Alaix
Zoetis

Juan Ramón Alaix was appointed chief executive officer of Zoetis in July 2012. In this role, he leads the world’s largest company with a singular focus on animal health medicines and vaccines. He is a member of the Zoetis Board of Directors. Mr. Alaix served as President of Pfizer Animal Health since 2006, where he was responsible for the overall strategic direction and financial performance of the company. Under his leadership, the company generated annual revenue of $4.8 billion in 2015 with approximately 9,000 employees worldwide. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. He joined Pfizer from Pharmacia in 2003 as Regional President. He has 35 years’ experience of increasing responsibility in finance, commercial and management, including 20 years in the pharmaceutical industry. In the 1990s, Mr. Alaix served in general management with Rhône-Poulenc Rorer in Spain and Belgium before becoming country President of Spain for Pharmacia in 1998. In 2013, Mr. Alaix completed a two-year term as President of the International Federation for Animal Health (IFAH), now known as HealthforAnimals, in addition to serving as a member of the board and executive committee. HealthforAnimals represents manufacturers of veterinary medicines, vaccines and other animal health products in both developed and emerging markets. Mr. Alaix continues to serve as a member of the HealthforAnimals board and executive committee. A native of Spain, Mr. Alaix received a graduate degree in economics from the Universidad de Madrid.

Satya Chava
Aptuit

Satya Chava is a Chief Executive Officer at Aptuit and is based in Greenwich, CT area.

Mr. John Golubieski
Fougera Pharmaceuticals

Mr. John Golubieski is a President and Chief Executive Officer at Fougera Pharmaceuticals Inc and is based in United States.

Mark Trudeau
Mallinckrodt

Carsten Hellmann
Merial Limited

Heather Bresch
Mylan

Heather Manchin Bresch (Manchin; born June 27, 1969) is an American business executive. In 2012, she was named as the chief executive officer (CEO) of Netherlands-based pharmaceutical company Mylan, becoming the first woman to run a Fortune 500 pharmaceutical company. Bresch retired in 2020, upon the closing of Mylan’s combination with Upjohn. In 2015, she was listed as #22 in Fortune magazine's “Most Powerful Women” list.

Severin Schwan
Roche Holding AG

Elanco competitors FAQs

Search for jobs